It only takes one drug to produce massive returns, as Seattle Genetics (SGEN), Medivation (MDVN), and Regeneron Pharmaceuticals (REGN 0.44%) have shown. Click on the slideshow below to learn more about their drugs, and find three more companies that are hoping to become one-drug wonders this year.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
3 One-Drug Biotech Wonders: Seattle Genetics, Medivation, and Regeneron
By Brian Orelli, PhD
–
Jan 31, 2014 at 6:30PM
NASDAQ: MDVN
Medivation, Inc.
For Seattle Genetics, Medivation, and Regeneron, one drug is enough.
Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Seattle Genetics. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Medivation, Inc.
MDVN
Regeneron Pharmaceuticals
REGN
$531.55
(0.44%)
$2.31
Seagen
SGEN
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
2 Biotech Stocks that Turned $8,000 into over $250,000
Is Pfizer Paying Too Much to Buy Medivation?
What's Up With Mylan's EpiPen Pricing?
3 Stocks Up Over 1,000% in the Past 5 Years
What Pfizer Gets in Its $14 Billion Medivation Deal
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.